Published in Cancer Weekly, January 16th, 2001
"This is the third drug candidate arising from our successful long term cancer drug discovery alliance with Pfizer to enter clinical trials," stated Colin Goddard, PhD, OSI Pharmaceuticals, Inc. "Moving forward we will continue our focus on the discovery and development of promising small molecule candidates, that are directed against specific gene targets involved in major disease areas including cancer."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.